Top Markets
Coin of the day
Genflow Biosciences Plc Genflow Biosciences Plc

Genflow Biosciences Plc

GENF
株式のランク #40421
Genflow Biosciences plc, together with its subsidiaries, engages in the... Genflow Biosciences plc, together with its subsidiaries, engages in the research and development of gene therapy targeting the upstream biology of aging in the United Kingdom and Belgium. The company operates as a pre-clinical biotechnology company that focuses on developing biological interventions aimed at tackling the effects of aging, slowing, and halting the aging process, as well as reducing the incidence of age-related diseases. Its lead drug candidate is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. The company is also developing GF-1003, a topical delivery of SIRT6 to the fibroblasts in the skin; GF-1004, a non-human pipeline anti-aging for veterinary use; GF-1005, which addresses mitochondrial dysfunction observed in sarcopenia for muscle health and combat sarcopenia; and GF-1006, an ophthalmology mRNA cent SIRT6 for the treatment of cornea pathologies and glaucoma. The company has collaborative research agreements with Revatis SA and EXO Biologics for therapy medicinal products. Genflow Biosciences plc was founded in 2020 and is headquartered in London, the United Kingdom.
株価
$0.02653368
時価総額
$150.29K
変化(1日)
-4.41%
変化(1年)
194.29%
GB
取引 Genflow Biosciences Plc (GENF)

カテゴリー

Genflow Biosciences Plc(GENF)の配当利回りの履歴
Genflow Biosciences Plc(銘柄コード: GENF)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Genflow Biosciences Plc(GENF)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)